Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
391 P53 AS A UTILITY MARKER FOR RISK ASSESSMENT IN BARRETT’S OESOPHAGUS
View through CrossRef
Abstract
Staging and prognosis of a case of Barrett's oesophagus is done by identifying the presence and grade of dysplasia. However, this method is highly subjective and can yield inaccurate diagnoses and prognoses. Demonstration of accumulation of p53 protein may be the most accurate and definitive approach to prognosticating cases of Barrett's oesophagus. This study focuses on p53 protein as a biomarker by immunohistochemistry staining in slides of different progression and demonstrates its promising clinical application.
Methods
Of 6175 endoscopies, from 970 cases of oesophagitis, a pilot study was performed on 6 cases of pathologically proven Barrett’s oesophagus, including a case with low-grade dysplasia, a case with high grade dysplasia and one case of poorly differentiated adenocarcinoma. Formalin fixed paraffin embedded tissue sections of the above cases were stained for anti p53 antibodies. The elevated immunohistochemical expression was quantified microscopically and a comparative analysis was done.
Results
p53 staining analysis showed significant immunoreactivity in the case of adenocarcinoma of oesophagus with diffuse strong nuclear staining. Low grade dysplasia and high grade dysplasia showed strong nuclear staining in the involved epithelium with focal and variable intensity positivity in the metaplastic epithelium. Those of reflux oesophagitis showed no nuclear staining in the epithelium. This pattern of staining with histological correlation is in concordance with other similar studies done supporting p53 as one of the crucial biomarkers for increased risk for carcinoma.
Conclusion
Increased p53 expression shows association with the higher risk of histological progression in the Barrett’s- carcinoma sequence. With the available literature p53 immunohistochemical staining along with other biomarkers will help us to predict the high risk patients and help treating clinician follow up the high risk patients. p53 shows promising utility as a part of panel for Barrett’s oesophagus and the spectrum.
Oxford University Press (OUP)
Title: 391 P53 AS A UTILITY MARKER FOR RISK ASSESSMENT IN BARRETT’S OESOPHAGUS
Description:
Abstract
Staging and prognosis of a case of Barrett's oesophagus is done by identifying the presence and grade of dysplasia.
However, this method is highly subjective and can yield inaccurate diagnoses and prognoses.
Demonstration of accumulation of p53 protein may be the most accurate and definitive approach to prognosticating cases of Barrett's oesophagus.
This study focuses on p53 protein as a biomarker by immunohistochemistry staining in slides of different progression and demonstrates its promising clinical application.
Methods
Of 6175 endoscopies, from 970 cases of oesophagitis, a pilot study was performed on 6 cases of pathologically proven Barrett’s oesophagus, including a case with low-grade dysplasia, a case with high grade dysplasia and one case of poorly differentiated adenocarcinoma.
Formalin fixed paraffin embedded tissue sections of the above cases were stained for anti p53 antibodies.
The elevated immunohistochemical expression was quantified microscopically and a comparative analysis was done.
Results
p53 staining analysis showed significant immunoreactivity in the case of adenocarcinoma of oesophagus with diffuse strong nuclear staining.
Low grade dysplasia and high grade dysplasia showed strong nuclear staining in the involved epithelium with focal and variable intensity positivity in the metaplastic epithelium.
Those of reflux oesophagitis showed no nuclear staining in the epithelium.
This pattern of staining with histological correlation is in concordance with other similar studies done supporting p53 as one of the crucial biomarkers for increased risk for carcinoma.
Conclusion
Increased p53 expression shows association with the higher risk of histological progression in the Barrett’s- carcinoma sequence.
With the available literature p53 immunohistochemical staining along with other biomarkers will help us to predict the high risk patients and help treating clinician follow up the high risk patients.
p53 shows promising utility as a part of panel for Barrett’s oesophagus and the spectrum.
Related Results
High P53 Protein Expression Level Independent of Mutational Status Is An Adverse Prognostic Factor for Survival in Acute Myeloid Leukemia
High P53 Protein Expression Level Independent of Mutational Status Is An Adverse Prognostic Factor for Survival in Acute Myeloid Leukemia
Abstract
Abstract 1490
Background:
The tumor suppressor p53 is frequently mutated in human cancer, including acut...
Abstract 1706: Investigating the interaction between ETS family members and mutant p53
Abstract 1706: Investigating the interaction between ETS family members and mutant p53
Abstract
Cancer cases are on the rise globally requiring a deeper understanding of the disease and identification of novel therapeutic targets. Mutations in genes of...
Abstract 3500: Mitochondrially targeted p53 domains as a stand alone or adjunct to paclitaxel for the treatment of ovarian cancer
Abstract 3500: Mitochondrially targeted p53 domains as a stand alone or adjunct to paclitaxel for the treatment of ovarian cancer
Abstract
Although the main function of p53 is a nuclear transcription factor that has important roles in cell cycle arrest, DNA repair, and apoptosis, p53 can direct...
Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2
Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2
The AP-1 protein complex primarily consists of several proteins from the c-Fos, c-Jun, activating transcription factor (ATF), and Jun dimerization protein (JDP) families. JDP2 has ...
Abstract 599: Id4 acts as a tumor suppressor by inducing apoptosis and senescence in p53-dependent manner
Abstract 599: Id4 acts as a tumor suppressor by inducing apoptosis and senescence in p53-dependent manner
Abstract
The physiological mechanisms that can restore biological activity of mutant p53 is an area of high interest given that mutant p53 expression is observed in ...
Abstract 422: Novel approach to destabilization of oncogenic mutant p53 and therapeutic implications
Abstract 422: Novel approach to destabilization of oncogenic mutant p53 and therapeutic implications
Abstract
Introduction: Mutant p53 drives several hallmarks of cancer through a gain-of-function oncogenic program. The oncogenicity of mutant p53 includes sustained ...
Supp. Figs. 1-12 from Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination
Supp. Figs. 1-12 from Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination
<p>Supplementary figures (1-12) Supplemental Fig. 1. Normalized levels of monoubiquitinated mutant p53 are shown for indicated cell lines analyzed in Fig. 1a. Supplemental Fi...
Supp. Figs. 1-12 from Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination
Supp. Figs. 1-12 from Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination
<p>Supplementary figures (1-12) Supplemental Fig. 1. Normalized levels of monoubiquitinated mutant p53 are shown for indicated cell lines analyzed in Fig. 1a. Supplemental Fi...